Lexicon's telotristat etiprate achieves positive top-line results in second Phase III trial

USA-based Lexicon Pharmaceuticals (Nasdaq: LXRX) says that top-line data from its TELECAST Phase III study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors consistent with the clinical benefit observed in its pivotal TELESTAR study.

Lexicon has a license and collaboration agreement with French drugmaker Ipsen (Euronext: IPN) to commercialize telotristat etiprate in Europe and other countries outside the USA and Japan (The Pharma Letter October 22, 2014).

The TELECAST study was designed as a companion to TELESTAR primarily to provide additional safety exposure while further evaluating telotristat etiprate's activity in carcinoid syndrome.